Scinai acquires Recipharm Israel to expand global reach
This transaction fundamentally strengthens Scinai's CDMO platform
This transaction fundamentally strengthens Scinai's CDMO platform
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Iberdomide has the potential to be the first approved CELMoD agent
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
Subscribe To Our Newsletter & Stay Updated